2C-T-7
Template:Short description Template:Use mdy dates Template:Cs1 config Template:Main other <templatestyles src="Infobox drug/styles.css"/> {{#invoke:Infobox|infobox}}Template:Template other{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= biosimilars= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= container_only= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= DTXSID= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= class6= component1= component2= component3= component4= component5= component6= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= image_class= image_class2= image_classL= image_classR= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_AU_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= DTXSID2= QID= QID2=PLLR= pregnancy_US= pregnancy_US_comment= |cat=Pages using infobox drug with unknown parameters |format=0|errNS=0
|preview=
}}{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =
| _has_physiological_data= | _has_gene_therapy=
| vaccine_type= | mab_type= | _number_of_combo_chemicals={{#invoke:ParameterCount |main |component1 |component2 |component3 |component4|component5|component6 }} | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=132112COc1cc(SCCC)c(cc1CCN)OC1S/C13H21NO2S/c1-4-7-17-13-9-11(15-2)10(5-6-14)8-12(13)16-3/h8-9H,4-7,14H2,1-3H3OLEVEPDJOFPJTF-UHFFFAOYSA-NTemplate:StdinchiciteTemplate:Stdinchicite206207 | _combo_data= | _physiological_data= | _clinical_data= Oral<ref name="PiHKAL" />Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; HallucinogenNone | _legal_data=F2Schedule IIISchedule I
| _other_data=2-[2,5-dimethoxy-4-(propylsulfanyl)phenyl]ethan-1-amine
| _image_0_or_2 = 2C-T-7 2DACS.svg2C-T-7-3d-sticks.png | _image_LR =
| _datapage = 2C-T-7 (data page) | _vaccine_target={{#ifeq: | vaccine | | _type_not_vaccine }} | _legal_all=F2Schedule IIISchedule I | _ATC_prefix_supplemental=None | _has_EMA_link = | CAS_number=207740-26-9 | PubChem=24728635 | ChemSpiderID=21106233 | ChEBI= | ChEMBL=126432 | DrugBank= | KEGG=C22737 | _hasInChI_or_Key={{#if:1S/C13H21NO2S/c1-4-7-17-13-9-11(15-2)10(5-6-14)8-12(13)16-3/h8-9H,4-7,14H2,1-3H3OLEVEPDJOFPJTF-UHFFFAOYSA-N |yes}} | UNII=TJG366J9BA | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =
| _countSecondIDs={{#invoke:ParameterCount |main |CAS_number2 |ATC_prefix2 |PubChem2 |PubChemStructure2 |IUPHAR_ligand2 |DrugBank2 |ChemSpiderID2 |UNII2 |KEGG2 |ChEBI2 |ChEMBL2 |PDB_ligand2 |NIAID_ChemDB2 |SMILES2 |smiles2 |StdInChI2 |StdInChIKey2 |DTXCID2}} | _countIndexlabels={{#invoke:ParameterCount |main |index_label |index2_label}} | _trackListSortletter= |QID = |QID2 = |Verifiedfields=verified |Watchedfields=verified |verifiedrevid=477216761}}
2C-T-7, also known as 4-propylthio-2,5-dimethoxyphenethylamine or as Blue Mystic or 7th Heaven, is a psychedelic drug of the phenethylamine and 2C families.<ref name="PiHKAL">Template:Cite web</ref><ref name="ShulginManningDaley2011" /><ref name="Platoni2002" /><ref name="O'Connell2002" /> It is taken orally.<ref name="PiHKAL" />
2C-T-7 was first described in the scientific literature by Myron Stolaroff in 1990.<ref name="Stolaroff1990" /> It was developed by Alexander Shulgin and colleagues and was described in greater detail by them in 1991, including in Shulgin's book PiHKAL (Phenethylamines I Have Known and Loved).<ref name="Stolaroff1990" /><ref name="ShulginShulginJacob1991" /><ref name="PiHKAL" />
Use and effects
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2C-T-7's dose range as 10 to 30Template:Nbspmg orally and its duration as 8 to 15Template:Nbsphours.<ref name="PiHKAL" /> It produces psychedelic effects.<ref name="PiHKAL" /><ref name="Stolaroff1990" /><ref name="Hardison2000">Template:Cite web</ref><ref name="Murple2001">Template:Cite web</ref> In PiHKAL, Shulgin records that the hallucinations it produces are unique, and that the chemical may cause muscle tension and an altered vocal quality.<ref name="coleads">Template:Cite web</ref> Shulgin rated it as one of the "magical half-dozen" most important psychedelic phenethylamines, together with mescaline, 2C-B, and 2C-T-2.<ref name="PiHKAL" />
Interactions
2C-T-7 is metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B.<ref name="DeanStellpflugBurnett2013">Template:Cite journal</ref><ref name="TheobaldMaurer2007">Template:Cite journal</ref> Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C-T-7.<ref name="DeanStellpflugBurnett2013" /><ref name="TheobaldMaurer2007" /><ref name="HalmanKongSarris2024">Template:Cite journal</ref> This may result in overdose and serious toxicity.<ref name="HalmanKongSarris2024" /><ref name="DeanStellpflugBurnett2013" />
Toxicity and deaths
There have been at least three reported deaths related to 2C-T-7 use as of August 2007, mainly at insufflated (snorted) doses of 30 mg or more.<ref name="pmid14607005">Template:Cite journal</ref><ref>Template:Cite report</ref> In the fall of 2000, a young healthy male died following insufflation of an excessive amount of 2C-T-7. Two additional deaths reported in April 2001 have been linked to 2C-T-7. These two deaths were reported by the DEA as being the result of the co-abuse of 2C-T-7 with MDMA.<ref>Template:Cite web</ref>
In January 2002, Rolling Stone published an article about 2C-T-7 entitled "The New (legal) Killer Drug".<ref>"The New (Legal) Killer Drug". Rolling Stone, January 10, 2002, issue 888: 44–49.</ref> Although the article suggested that the drug was legal, the legal status of 2C-T-7 was ambiguous at the time due to the United States' Federal Analogue Act.<ref>21 USC §813</ref> A detailed response on the website disinfo.com challenged the accuracy of much of the reporting in the aforementioned Rolling Stone article.<ref>Template:Cite web</ref> 2C-T-7 has since been officially made illegal and declared a schedule 1 substance in the United States.<ref name="s320"/>
The Partnership for a Drug-Free America reported in 2006 that 2C-T-7 can be lethal even in small doses;<ref>Template:Cite web</ref> however, they provide no source for their claim and of the three known deaths (as of August 2007) of 2C-T-7 intoxicated individuals, all involved either uncommonly large insufflated doses or the concomitant ingestion of other stimulants such as ephedrine and/or MDMA.
All of the three aforementioned known deaths of individuals under the influence of 2C-T-7 occurred in those known to be either intoxicated with other stimulants such as ephedrine or MDMA (which are known to be potentially lethal in certain situations or at excessive doses)<ref>Template:Cite journal</ref> or after the individual insufflated an amount of 2C-T-7 much greater than necessary to induce the full range of effects typically sought after by users of the drug; for example, the reported 35 mg insufflated dose taken by the individual who died in the fall of 2000. This reported dose was characterized as "excessive" by the United States DEA.
Pharmacology
Pharmacodynamics
The mechanism that produces the psychedelic effects of 2C-T-7 is most likely to result from action as a 5-HT2A serotonin receptor agonist in the brain, a mechanism of action shared by most currently-known hallucinogenic tryptamines and phenethylamines.<ref name="FantegrossiHarringtonEckler2005">Template:Cite journal</ref> 2C-T-7 has structural and pharmacodynamic properties similar to those of 2C-T-2.<ref name="PiHKAL" />
Chemistry
Synthesis
The chemical synthesis of 2C-T-7 has been described.<ref name="PiHKAL" /><ref name="ShulginManningDaley2011">Template:Cite book</ref>
History
2C-T-7 was first described in the scientific literature by Myron Stolaroff by 1990.<ref name="Stolaroff1990">Template:Cite journal</ref> It was developed by Alexander Shulgin and Peyton Jacob III.<ref name="Stolaroff1990" /><ref name="ShulginShulginJacob1991" /><ref name="PiHKAL" /> Subsequently, 2C-T-7 was described in greater detail by Shulgin and colleagues in 1991.<ref name="ShulginShulginJacob1991">Template:Cite journal</ref><ref name="PiHKAL" />
Up until Operation Web Tryp and three deaths, two of which involved the use of other drugs in addition to 2C-T-7, and one which involved an excessive insufflated dose, 2C-T-7 was sold commercially in Dutch and Japanese smartshops and online.<ref name="Platoni2002">Template:Cite news</ref><ref name="O'Connell2002">Template:Cite web</ref>
Society and culture
Legal status
Around the year 2000, 2C-T-7 began to change from an obscure chemical to a drug used at parties and clubs in North America and Europe as it became available through a number of grey-market commercial vendors. This aroused the attention of the authorities, and many countries have since scheduled the chemical.
Australia
In Australia, 2C-T-2 and 2C-T-7 are covered by the country's analogue drug laws.
Canada
As of October 31, 2016, 2C-T-7 is a controlled substance (Schedule III) in Canada.<ref>Template:Cite web</ref>
China
As of October 2015 2C-T-7 is a controlled substance in China.<ref>Template:Cite web</ref>
Finland
2C-T-7 is scheduled in the "government decree on substances, preparations and plants considered to be narcotic drugs".<ref>Template:Cite web</ref>
Germany
2C-T-7 is scheduled in Germany. (BTMG)
Netherlands
The Netherlands was the first country in the world to ban 2C-T-7, after being sold in smartshops for a short period. After 2C-T-2 was first banned, 2C-T-7 quickly appeared on the market, but was soon banned as well. 2C-T-7 is a list I drug of the Opium Law.
Sweden
Schedule I in Sweden.<ref>Template:Cite web</ref> 2C-T-7 was first classified as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of April 1, 1999, under SFS 1999:58<ref>Template:Cite web</ref> that made it illegal to sell or possess.
United Kingdom
In 1999, Alexander Shulgin was sent a copy of a letter from the British Home Office to several of its administrative associates that in effect placed all compounds listed in PiHKAL into Class A.Template:Citation needed
United States
On September 20, 2002, 2C-T-7 was classified as a Schedule I substance in the United States by an emergency ruling by the DEA. On March 18, 2004, the DEA published a Final Rule in the Federal Register permanently placing 2C-T-7 in Schedule I. (69 FR 12794)<ref name="s320"/><ref>Template:Cite web</ref><ref>Template:Cite web</ref>
As of April 2024, law enforcement have encountered 2C-T-7 in 16 states, with the highest number of encounters being in Florida. Purchases made over the internet are believed by the DEA to be the most common source by which users of the drug acquire it in the United States, and one laboratory manufacturing the drug was discovered by police in Las Vegas, Nevada.<ref name="s320">Template:Cite web</ref>
See also
References
External links
- 2C-T-7 - Isomer Design
- 2C-T-7 - PsychonautWiki
- 2C-T-7 - Erowid
- 2C-T-7 - PiHKAL - Erowid
- 2C-T-7 - PiHKAL - Isomer Design
- 2C-T-7: A Mixed Bag of Psychedelic Tricks - Tripsitter
Template:Psychedelics Template:Serotonin receptor modulators Template:TAAR modulators Template:Phenethylamines